Cargando…

COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient

A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Ryo, Kubota-Koketsu, Ritsuko, Lu, Xiuyuan, Sasaki, Tadahiro, Nakayama, Emi E., Liu, Yu-chen, Okuzaki, Daisuke, Motooka, Daisuke, Wing, James Badger, Fujikawa, Yasunori, Ichida, Yuji, Amo, Kiyoko, Goto, Tetsushi, Hara, Junichi, Shirano, Michinori, Yamasaki, Sho, Shioda, Tatsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116114/
https://www.ncbi.nlm.nih.gov/pubmed/37124420
http://dx.doi.org/10.1016/j.isci.2023.106685
_version_ 1785028353939472384
author Morita, Ryo
Kubota-Koketsu, Ritsuko
Lu, Xiuyuan
Sasaki, Tadahiro
Nakayama, Emi E.
Liu, Yu-chen
Okuzaki, Daisuke
Motooka, Daisuke
Wing, James Badger
Fujikawa, Yasunori
Ichida, Yuji
Amo, Kiyoko
Goto, Tetsushi
Hara, Junichi
Shirano, Michinori
Yamasaki, Sho
Shioda, Tatsuo
author_facet Morita, Ryo
Kubota-Koketsu, Ritsuko
Lu, Xiuyuan
Sasaki, Tadahiro
Nakayama, Emi E.
Liu, Yu-chen
Okuzaki, Daisuke
Motooka, Daisuke
Wing, James Badger
Fujikawa, Yasunori
Ichida, Yuji
Amo, Kiyoko
Goto, Tetsushi
Hara, Junichi
Shirano, Michinori
Yamasaki, Sho
Shioda, Tatsuo
author_sort Morita, Ryo
collection PubMed
description A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4(+) T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4(+) T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health.
format Online
Article
Text
id pubmed-10116114
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101161142023-04-20 COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient Morita, Ryo Kubota-Koketsu, Ritsuko Lu, Xiuyuan Sasaki, Tadahiro Nakayama, Emi E. Liu, Yu-chen Okuzaki, Daisuke Motooka, Daisuke Wing, James Badger Fujikawa, Yasunori Ichida, Yuji Amo, Kiyoko Goto, Tetsushi Hara, Junichi Shirano, Michinori Yamasaki, Sho Shioda, Tatsuo iScience Article A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4(+) T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4(+) T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health. Elsevier 2023-04-20 /pmc/articles/PMC10116114/ /pubmed/37124420 http://dx.doi.org/10.1016/j.isci.2023.106685 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Morita, Ryo
Kubota-Koketsu, Ritsuko
Lu, Xiuyuan
Sasaki, Tadahiro
Nakayama, Emi E.
Liu, Yu-chen
Okuzaki, Daisuke
Motooka, Daisuke
Wing, James Badger
Fujikawa, Yasunori
Ichida, Yuji
Amo, Kiyoko
Goto, Tetsushi
Hara, Junichi
Shirano, Michinori
Yamasaki, Sho
Shioda, Tatsuo
COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient
title COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient
title_full COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient
title_fullStr COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient
title_full_unstemmed COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient
title_short COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient
title_sort covid-19 relapse associated with sars-cov-2 evasion from cd4(+) t-cell recognition in an agammaglobulinemia patient
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116114/
https://www.ncbi.nlm.nih.gov/pubmed/37124420
http://dx.doi.org/10.1016/j.isci.2023.106685
work_keys_str_mv AT moritaryo covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT kubotakoketsuritsuko covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT luxiuyuan covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT sasakitadahiro covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT nakayamaemie covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT liuyuchen covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT okuzakidaisuke covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT motookadaisuke covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT wingjamesbadger covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT fujikawayasunori covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT ichidayuji covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT amokiyoko covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT gototetsushi covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT harajunichi covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT shiranomichinori covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT yamasakisho covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient
AT shiodatatsuo covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient